2010 Buenos Aires, Argentina

Total Page:16

File Type:pdf, Size:1020Kb

2010 Buenos Aires, Argentina Claiming CME Credit To claim CME credit for your participation in the MDS 14th Credit Designation International Congress of Parkinson’s Disease and Movement The Movement Disorder Society designates this educational Disorders, International Congress participants must complete activity for a maximum of 35 AMA PRA Category 1 Credits™. and submit an online CME Request Form. This form will be Physicians should only claim credit commensurate with the available beginning June 15. extent of their participation in the activity. Instructions for claiming credit: If you need a Non-CME Certificate of Attendance, please tear • After June 15, visit the MDS Web site. out the Certificate in the back of this Program and write in • Log in after reading the instructions on the page. You will your name. need your International Congress File Number which is located on your name badge or e-mail The Movement Disorder Society has sought accreditation from [email protected]. the European Accreditation Council for Continuing Medical • Follow the on-screen instructions to claim CME Credit for Education (EACCME) to provide CME activity for medical the sessions you attended. specialists. The EACCME is an institution of the European • You may print your certificate from your home or office, or Union of Medical Specialists (UEMS). For more information, save it as a PDF for your records. visit the Web site: www.uems.net. Continuing Medical Education EACCME credits are recognized by the American Medical The Movement Disorder Society is accredited by the Association towards the Physician’s Recognition Award (PRA). Accreditation Council for Continuing Medical Education To convert EACCME credit to AMA PRA category 1 credit, (ACCME) to provide continuing medical education for contact the AMA online at www.ama-assn.org. physicians. 2 T14thhe M Internationalovement D Congressisorder S ofoc Parkinson’siety Disease and Movement Disorders Contents Welcome Letter . .2 About MDS . 4 Education Information . 8 Membership Information . 16 International Congress Information Speaker Ready Room Hours . .19 Registration Hours . 19 Poster Sessions Hours . 21 Social Events . .23 Sheraton Floor Plans . .24 Awards Information . 25 CME Information . .30 Program-at-a-Glance . .31 Session Definitions . .32 Scientific Program . .33 Faculty Listing . 56 Corporate Therapeutic Symposia . 60 Exhibitor Information . 63 Exhibitor Directory . 64 Exhibit Hall Floor Plan . .69 Guided Poster Tours Information . 71 Abstract Listing by Topic . 81 1 Welcome Dear Colleagues and Friends, Welcome to Buenos Aires for the 14th International Congress of Parkinson’s Disease and Movement Disorders! We would like to express our gratitude to the large number of our volunteer committees for designing this International Congress including Congress Local Organizing Committee for their hard work in arranging the Congress social events that we are sure you will enjoy. We would especially like to thank the Congress Scientific Program Committee for their hard work and coordination of this superior Scientific Program. The 2010 Scientific Program will incorporate Therapeutic Plenary Sessions, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Guided Poster Tours and Blue Ribbon Highlights. This year’s program features 66 sessions led by over 170 esteemed faculty from around the world. While in Buenos Aires, we hope you not only allot time in your schedule to participate in our detailed program, visit the exhibit and poster areas and attend the social events in the evenings, but also get a chance to see the sights and sounds of what makes Buenos Aires such a unique destination. Thank you for your support of The Movement Disorder Society and welcome to our 14th International Congress of Parkinson’s Disease and Movement Disorders. Philip D. Thompson Christopher G. Goetz Oscar Gershanik President, Chair, Co-Chair, The Movement Disorder Society, Congress Scientific Program Committee, Congress Scientific Program Committee, 2009-2011 2009-2011 2010 2 T14thhe M Internationalovement D Congressisorder S ofoc Parkinson’siety Disease and Movement Disorders Acknowledgements The International Congress Oversight Committee of the 14th International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge and thank the following companies for their support: PLATINUM LEVEL GOLD LEVEL SILVER LEVEL *These companies are confirmed as of April 15, 2010 3 About MDS The Movement Disorder Society (MDS) is an international, PURPOSE, MISSION AND GOALS professional society of clinicians, scientists and other Purpose: healthcare professionals who are interested in Parkinson’s The objective and mission of the Society shall be to advance disease, related neurodegenerative and neurodevelopmental About MDS the neurological sciences pertaining to Movement Disorders; disorders, hyperkinetic movement disorders and abnormalities to improve the diagnosis and treatment of patients; to operate in muscle tone and motor control. The spectrum of clinical exclusively for scientific, scholarly and educational purposes; disorders represented by the Society includes, but is not to encourage research; to provide forums, such as medical limited to: journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and Ataxia scientific disciplines; to encourage interest and participation Blepharospasm in the activities of the Society among healthcare and allied Dysphonia professionals and scientists; and to collaborate with other Dystonic disorders related professional and lay organizations. Gait disorders Huntington’s disease Mission and Goals: Myoclonus To disseminate knowledge about Movement Disorders by: Parkinson’s disease • Providing educational programs for clinicians, scientists and Restless legs syndrome the general public designed to advance scientific and clinical Spasticity knowledge about Movement Disorders; Tardive dyskinesia • Sponsoring congresses and symposia on Movement Tics and Tourette syndrome Disorders; Tremor • Collaborating with other international organizations and lay groups; The Movement Disorder Society (MDS) was founded in 1985 • Publishing journals, videotapes and other collateral materials on the initiative of Professors Stanley Fahn and C. David committed to high scientific standards and peer review. Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. The organization To promote research into causes, prevention and treatment of merged in 1988 with the International Medical Society for movement disorders by: Motor Disturbances. • Using the Society’s influence and resources to enhance support for research; • Facilitating the dissemination of information about research; • Encouraging the training of basic and clinical scientists in movement disorders and related disorders. For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to: • Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions; • The public (media) and patient support groups by informing them of new research and therapeutic advances; • Governments to assist them in the development of policies that affect support of research and patient care; • Educational efforts to assist in developing standards of training in the specialty. 4 T14thhe M Internationalovement D Congressisorder S ofoc Parkinson’siety Disease and Movement Disorders About MDS About MDS MDS OFFICERS (2009-2011) President President-Elect Secretary Secretary-Elect Treasurer Treasurer-Elect Past-President Philip Thompson, Günther Deuschl, Matthew Stern, Cynthia Comella, Oscar Gershanik, Nir Giladi, Anthony Lang, Australia Germany USA USA Argentina Israel Canada MDS INTERNATIONAL CONGRESS SCIENTIFIC EXECUTIVE COMMITTEE PROGRAM COMMITTEE Giovanni Abbruzzese, Italy Chair: Christopher Goetz, USA Alim Benabid, France Co-Chair: Oscar Gershanik, Argentina Kailash Bhatia, United Kingdom Roger Barker, United Kingdom David John Burn, United Kingdom Kailash Bhatia, United Kingdom Ryuji Kaji, Japan David John Burn, United Kingdom Irene Litvan, USA Francisco Cardoso, Brazil Serge Przedborski, USA Ted Dawson, USA Cristina Sampaio, Portugal Günther Deuschl, Germany A. Jon Stoessl, Canada Dennis Dickson, USA Giovanni Fabbrini, Italy INTERNATIONAL CONGRESS Susan Fox, Canada OVERSIGHT COMMITTEE Thomas Gasser, Germany Chair: Andrew Lees, United Kingdom Etienne Hirsch, France Günther Deuschl, Germany Christine Klein, Germany Oscar Gershanik, Argentina Joachim Krauss, Germany Anthony Lang, Canada Andrew Lees, United Kingdom C. Warren Olanow, USA Irene Litvan, USA Philip Thompson, Australia Pablo Martinez-Martin, Spain Ad-Hoc: Christopher Goetz, USA Marcelo Merello, Argentina Per Odin, Germany Henry Paulson, USA Ronald Pfeiffer, USA Serge Przedborski, USA Kapil Sethi, USA Louis Tan, Singapore Daniel Tarsy, USA Philip Thompson, Australia Marie Vidailhet, France 5 About MDS CONGRESS LOCAL ORGANIZING INTERNATIONAL MEDICAL SOCIETY FOR COMMITTEE MOTOR DISTURBANCES PAST-PRESIDENTS Chair: Oscar Gershanik 1993-1994 C. Warren Olanow, USA About MDS Tomoko Arakaki 1991-1992 Bastian Conrad, Germany José Bueri 1989-1990 Mark Hallett, USA Anabel Chade 1987-1988 Mario Manfredi, Italy Silvia García 1985-1986 C. David Marsden, United Kingdom Nélida Garretto Emilia Gatto MDS INTERNATIONAL SECRETARIAT Rolando Giannaula The Movement Disorder Society
Recommended publications
  • Seventy-Ninth Annual Pulaski Day Parade Sunday, October 2, 2016 Fifth Avenue, New York City
    Preliminary LONG version As of 10/1/16 SEVENTY-NINTH ANNUAL PULASKI DAY PARADE SUNDAY, OCTOBER 2, 2016 FIFTH AVENUE, NEW YORK CITY MARCH 4, OCTOBER 11, 1745 1779 2016 PULASKI PARADE GRAND MARSHAL HON. DR. DONNA KOCH-KAPTURSKI Specializes in Family Medicine and Internal Medicine in Garfield, NJ. HONORARY MARSHALS ANNA MARIA ANDERS DAUGHTER OF GENERAL WLADYSLAW ANDERS POLISH SENATOR AND PROCURATOR OF THE SECRETARY OF STATE OF THE COUNCIL OF MINISTERS FOR INTERNATIONAL DIALOGUE STANISLAW KARCZEWSKI MARSHAL OF THE SENATE OF THE REPUBLIC OF POLAND BILL SHIBILSKI RADIO HOST, BROADCASTER AND PAST MC OF THE PULASKI DAY PARADE PRESIDENT RICHARD ZAWISNY GENERAL PULASKI MEMORIAL PARADE COMMITTEE, INC. Page 1 of 57 Preliminary LONG version As of 10/1/16 ASSEMBLY STREETS 39A 6TH 5TH AVE. AVE. M A 38 FLOATS 21-30 38C FLOATS 11-20 38B 38A FLOATS 1 - 10 D I S O N 37 37C 37B 37A A V E 36 36C 36B 36A 6TH 5TH AVE. AVE. Page 2 of 57 Preliminary LONG version As of 10/1/16 PRESIDENT’S MESSAGE THE 79TH ANNUAL PULASKI DAY PARADE COMMEMORATING THE SACRIFICE OF OUR HERO, GENERAL CASIMIR PULASKI, FATHER OF THE AMERICAN CAVALRY, IN THE WAR OF AMERICAN INDEPENDENCE BEGINS ON FIFTH AVENUE AT 12:30 PM ON SUNDAY, OCTOBER 2, 2016. THIS YEAR WE ARE CELEBRATING “POLISH- AMERICAN YOUTH, IN HONOR OF WORLD YOUTH DAY, KRAKOW, POLAND” IN 2016. THE ‘GREATEST MANIFESTATION OF POLISH PRIDE IN AMERICA’ THE PULASKI PARADE, WILL BE LED BY THE HONORABLE DR. DONNA KOCH- KAPTURSKI, A PROMINENT PHYSICIAN FROM THE STATE OF NEW JERSEY.
    [Show full text]
  • 2006 Volkswagen Pro Tour Grand Finals Participating Players List (Updated As at 13/12/2006)
    2006 Volkswagen Pro Tour Grand Finals Participating Players List (updated as at 13/12/2006) Men’s Singles Women’s Singles 01 MA Lin (CHN) ZHANG Yining (CHN) 02 WANG Liqin (CHN) WANG Yue Gu (SIN) 03 BOLL Timo (GER) *TIE Yana (HKG) 04 CHEN Qi (CHN) WANG Nan (CHN) 05 SAMSONOV Vladimir (BLR) LI Jia Wei (SIN) 06 WANG Hao (CHN) *JIANG Huajun (HKG) 07 HOU Yingchao (CHN) GUO Yan (CHN) 08 OH Sang Eun (KOR) LI Xiaoxia (CHN) 09 JOO Se Hyuk (KOR) LIU Jia (AUT) 10 CHEN Weixing (AUT) HIRANO Sayaka (JPN) 11 CHUAN Chih-Yuan (TPE) GAO Jun (USA) 12 SCHLAGER Werner (AUT) SHEN Yanfei (ESP) 13 *LI Ching (HKG) HIURA Reiko (JPN) 14 ELOI Damien (FRA) LI Jiao (NED) 15 GARDOS Robert (AUT) *ZHANG Rui (HKG) 16 KORBEL Petr (CZE) TAN MONFARDINI Wenling (ITA) Men’s Doubles Women’s Doubles 01 CHEN Qi / MA Lin (CHN) WANG Nan / ZHANG Yining (CHN) 02 CHEN Weixing / GARDOS Robert (AUT) *TIE Yana / ZHANG Rui (HKG) 03 *CHEUNG Yuk / LEUNG Chu Yan (HKG) GUO Yue / LI Xiaoxia (CHN) 04 *KO Lai Chak / LI Ching (HKG) LI Jia Wei / SUN Bei Bei (SIN) 05 BOLL Timo / SUSS Christian (GER) GAO Jun (USA) / SHEN Yanfei (ESP) 06 HAO Shuai / MA Long (CHN) HIRANO Sayaka / HIURA Reiko (JPN) 07 GAO Ning / YANG Zi (SIN) HEINE Veronika / LIU Jia (AUT) 08 AXELQVIST Johan / SVENSSON Robert (SWE) *LAU Sui Fei / LIN Ling (HKG) U21 Boys’ Singles U21 Girls’ Singles 01 *JIANG Tianyi (HKG) LI Qiangbing (AUT) 02 AXELQVIST Johan (SWE) POTA Georgina (HUN) 03 BAUM Patrick (GER) GRUNDISCH Carole (FRA) 04 BOBILLIER Loïc (FRA) RAMIREZ Sara (ESP) 05 JAKAB Janos (HUN) VACENOVSKA Iveta (CZE) 06 KIM Tae Hoon (KOR) *YU Kwok See (HKG) 07 MATSUMOTO Cazuo (BRA) HEINE Veronika (AUT) 08 DURAN Marc (ESP) PROKHOROVA Yulia (RUS) .
    [Show full text]
  • PRCUA Naród Polski
    Official Publication of the Polish Roman Catholic Union of America - The Oldest Polish American Fraternal 1873-2009 No. 15 - Vol. CXXIII September 1, 2009 - 1 Wrzesnia 2009 PRCUA Announces Two New Insurance Plans SEPTEMBER - Dear Current and Prospective Members: Life Insurance The year 2010 marks the Polish Roman Awareness Month Catholic Union of America’s 137th year of Awareness Month service to our members and the greater Polish These are unsettling times. Over the past American community. Additionally, our 60th year, almost every pillar of our financial security has been Quadrennial Convention will take place in shaken, one by one. The bursting of the real estate bubble, 2010 from August 8th to August 11th in the precipitous decline in the stock market, a rapid spike in Rosemont, Illinois. job losses. Now more than ever, Americans are searching for ways to maintain basic financial security. At this time, it is my esteemed pleasure to One source of financial security still stands strong, officially announce the Polish Roman Catholic however, and that’s life insurance. It continues to do what it Union of America’s 137th Anniversary was designed to do – serve as the foundation of your family’s Special. This is a 20-Year Limited Payment financial security. Whole Life Insurance Plan that contains cash If you own a term life policy, the death benefit it would value and no anticipated dividends. With the utilization of a $137 discount pay if you died tomorrow is unchanged from last week, last voucher, you will receive a credit of this amount towards the first year’s annual month or even last year.
    [Show full text]
  • D-Penicillamine-Induced Status Dystonicus in a Patient with Wilson’S Disease: a Diagnostic & Therapeutic Challenge
    A. Satyasrinivas, et al. D-penicillamine-induced Status Dystonicus | Case Report D-penicillamine-induced Status Dystonicus in A Patient with Wilson’s Disease: A Diagnostic & Therapeutic Challenge A. Satyasrinivas*, Y.S. Kanni, N.Rajesh, M.SaiSravanthi, Vijay kumar Department of General Medicine, Kamineni Institute Of Medical Sciences, Narketpally 508254 Andhra Pradesh, India. DOI Name http://dx.doi.org/10.3126/jaim.v3i2.14066 Keywords Dystonia,Gabapentin Kayser-Fleischer ring, ABSTRACT Trientein hydrochloride, Wilson’s disease. Wilson's disease is an autosomal-recessive disorder of copper metabolism Citation resulting from the absence or dysfunction of a copper-transporting protein. A. Satyasrinivas, Y.S. Kanni, N.Rajesh, The disease is mainly seen in children, adolescents and young adults, and is M.SaiSravanthi, Vijay kumar. D-penicillamine- induced Status Dystonicus in A Patient with characterized by hepatobiliary, neurologic, psychiatric and ophthalmologic Wilson’s Disease: A Diagnostic & Therapeutic (Kayser-Fleischer rings) manifestations. Mechanism of status dystonicus in WD Challenge. Journal of Advances in Internal Medicine is not clear We present here a case study of Wil. son’s disease in 14 year old 2014;03(01):62-64. child with dystonia not responed with routine therapy. INTRODUCTION but patient had developed loose stools, difficulty in speaking and pronouncing linguals. With these compliants he was Wilson’s disease (WD), also known as hepatolenticular admitted in the hospital. On Radio imaging and ophthalmic degeneration was first described in 1912 by Kinnear Wilson as examination he was diagnosed as a case of Wilson’s disease progressive lenticular degeneration. WD is an inherited, fatal and was started with tablet calcium Pantothenate and neurological disorder accompanied by chronic liver disease tablets D-Penicillamine and was discharged.
    [Show full text]
  • Section 1: MIT Facts and History
    1 MIT Facts and History Economic Information 9 Technology Licensing Office 9 People 9 Students 10 Undergraduate Students 11 Graduate Students 12 Degrees 13 Alumni 13 Postdoctoral Appointments 14 Faculty and Staff 15 Awards and Honors of Current Faculty and Staff 16 Awards Highlights 17 Fields of Study 18 Research Laboratories, Centers, and Programs 19 Academic and Research Affiliations 20 Education Highlights 23 Research Highlights 26 7 MIT Facts and History The Massachusetts Institute of Technology is one nologies for artificial limbs, and the magnetic core of the world’s preeminent research universities, memory that enabled the development of digital dedicated to advancing knowledge and educating computers. Exciting areas of research and education students in science, technology, and other areas of today include neuroscience and the study of the scholarship that will best serve the nation and the brain and mind, bioengineering, energy, the envi- world. It is known for rigorous academic programs, ronment and sustainable development, informa- cutting-edge research, a diverse campus commu- tion sciences and technology, new media, financial nity, and its long-standing commitment to working technology, and entrepreneurship. with the public and private sectors to bring new knowledge to bear on the world’s great challenges. University research is one of the mainsprings of growth in an economy that is increasingly defined William Barton Rogers, the Institute’s founding pres- by technology. A study released in February 2009 ident, believed that education should be both broad by the Kauffman Foundation estimates that MIT and useful, enabling students to participate in “the graduates had founded 25,800 active companies.
    [Show full text]
  • TABLE TENNIS Ολυµπιακό Γυµναστήριο Γαλατσίου Επιτραπέζια Αντισφαίριση / TENNIS DE TABLE Gymnase Olympique De Galatsi
    Galatsi Olympic Hall TABLE TENNIS Ολυµπιακό Γυµναστήριο Γαλατσίου Επιτραπέζια Αντισφαίριση / TENNIS DE TABLE Gymnase Olympique de Galatsi Medallists by Event Κάτοχοι Μεταλλίων ανά Αγώνισµα / Médaillés par épreuve AFTER 4 OF 4 EVENTS As of 23 AUG 2004 NOC Event Name Date Medal Name Code WANG Nan Women's Doubles 20 AUG 2004 GOLD CHN ZHANG Yining LEE Eun Sil SILVER KOR SEOK Eun Mi GUO Yue BRONZE CHN NIU Jianfeng CHEN Qi Men's Doubles 21 AUG 2004 GOLD CHN MA Lin KO Lai Chak SILVER HKG LI Ching MAZE Michael BRONZE DEN TUGWELL Finn Women's Singles 22 AUG 2004 GOLD ZHANG Yining CHN SILVER KIM Hyang Mi PRK BRONZE KIM Kyung Ah KOR Men's Singles 23 AUG 2004 GOLD RYU Seung Min KOR SILVER WANG Hao CHN BRONZE WANG Liqin CHN TT0000000_C93.4.0 Report Created MON 23 AUG 2004 14:50 Page 1/1 Galatsi Olympic Hall TABLE TENNIS Ολυµπιακό Γυµναστήριο Γαλατσίου Επιτραπέζια Αντισφαίριση / TENNIS DE TABLE Gymnase Olympique de Galatsi Medal Standings Κατάταξη Μεταλλίων / Répartition des médailles AFTER 4 OF 4 EVENTS As of MON 23 AUG 2004 Men Women Total Rank Rank NOC By G S B Tot G S B Tot G S B Tot Total 1 CHN - China 1 1 1 3 2 1 3 3 1 2 6 1 2 KOR - Korea 1 1 1 1 2 1 1 1 3 2 3 HKG - Hong Kong 1 1 1 1 =3 3 PRK - DPR Korea 1 1 1 1 =3 5 DEN - Denmark 1 1 1 1 =3 Total 2 2 2 6 2 2 2 6 4 4 4 12 Legend: G - Gold S - Silver B - Bronze Tot - Total '=' - Equal sign indicates that two or more player's NOCs share the same rank by total TT_C95 4.0 Report Created MON 23 AUG 2004 14:50 Page 1/1 Galatsi Olympic Hall TABLE TENNIS Ολυµπιακό Γυµναστήριο Γαλατσίου Επιτραπέζια Αντισφαίριση / TENNIS DE TABLE Gymnase Olympique de Galatsi 22 Aug.
    [Show full text]
  • Sten Grillner
    BK-SFN-HON_V9-160105-Grillner.indd 108 5/6/2016 4:11:20 PM Sten Grillner BORN: Stockholm, Sweden June 14, 1941 EDUCATION: University of Göteborg, Sweden, Med. Candidate (1962) University of Göteborg, Sweden, Dr. of Medicine, PhD (1969) Academy of Science, Moscow, Visiting Scientist (1971) APPOINTMENTS: Docent in Physiology, Medical Faculty, University of Göteborg (1969–1975) Professor, Department of Physiology III, Karolinska Institute (1975–1986) Director, Nobel Institute for Neurophysiology, Karolinska Institute, Professor (1987) Nobel Committee for Physiology or Medicine, Chair, 1995–1997 (1987–1998) Nobel Assembly at the Karolinska Institutet, Member Chair, 2005 (1988–2008) Chairman Department of Neuroscience, Karolinska Institutet (1993–2000) Distinguished Professor, Karolinska Institutet (2010) HONORS AND AWARDS: Member of Academiae Europaea 1990– Member of Royal Swedish Academy of Science 1993– Chairman Section for Biology and Member of Academy Board, 2004–2010 Member of Norwegian Academy of Science and Letters, 1997– Member American Academy of Arts and Sciences, 2004– Honorary Member of the Spanish Medical Academy, 2006– Foreign Associate of Institute of Medicine of the National Academy, United States, 2006– Foreign Associate of the National Academy, United States, 2010– Associate of the Neuroscience Institute, La Jolla, 1989– Member EMBO, 2014– Florman Award, Royal Swedish Academy of Science, 1977 Grass Lecturer to the Society of Neuroscience, Boston, 1983 Greater Nordic Prize of Eric Fernstrom, Lund, Sweden, 1990 Bristol-Myers
    [Show full text]
  • Mathematics Without Borders - Winter 2020 Group 1
    MATHEMATICS WITHOUT BORDERS - WINTER 2020 GROUP 1 Age № Full name of the participant Country City Award group 1 Abboskhodjaeva Mohasalkhon Uzbekistan Tashkent 1 Certificate 2 Abdel Karim Alya Maria Romania Bucharest 1 Certificate 3 Abdraimov Alan Kazakhstan Nur-Sultan 1 Certificate 4 Abdraimova Adiya Kazakhstan Nur-Sultan 1 Certificate 5 Abdujabborova Alizoda Uzbekistan Tashkent 1 Bronze 6 Abdullaev Amirbek Uzbekistan Tashkent 1 Certificate 7 Abdullaeva Dinara Uzbekistan Namangan 1 Silver 8 Abdullaeva Samiya Uzbekistan Tashkent 1 Certificate 9 Abdullah Balogun Nigeria Lagos 1 Certificate 10 Abdullayev Azam Uzbekistan Tashkent 1 Certificate 11 Abdullayev Mirolim Uzbekistan Tashkent 1 Silver 12 Abdullayev Saidumar Uzbekistan Tashkent 1 Certificate 13 Abdullayeva Diyora Uzbekistan Tashkent 1 Silver 14 Abdurahimov Abduhakim Uzbekistan Tashkent 1 Certificate 15 Abduvosidov Abbosbek Uzbekistan Namangan 1 Certificate 16 Abidov Islombek Uzbekistan Tashkent 1 Certificate 17 Abiyev Alan Kazakhstan Almaty 1 Certificate 18 Abriol, Willary A. Philippines Naga City 1 Silver 19 Abrolova Laylokhon Uzbekistan Tashkent 1 Silver 20 Abrorova Afruza Uzbekistan Tashkent 1 Certificate 21 Abulkhairova Amina Kazakhstan Atyrau 1 Certificate 22 Ada Arif Vasvi Bulgaria Isperih 1 Certificate 23 Ada Selim Selim Bulgaria Razgrad 1 Bronze 24 Adel Dzheyn Brand Bulgaria Bansko 1 Certificate 25 Adelina Dobrinova Angelova Bulgaria Varna 1 Bronze 26 Adelina Georgieva Ivanova Bulgaria Svishtov 1 Silver 27 Adelina Svetoslav Yordanova Bulgaria Kyustendil 1 Bronze 28 Adina Zaharieva
    [Show full text]
  • Modafinil/Armodafinil (Provigil ® /Nuvigil
    Drug and Biologic Coverage Policy Effective Date ............................................ 7/1/2020 Next Review Date… ..................................... 7/1/2021 Coverage Policy Number .................................. 1501 Modafinil / Armodafinil for Individual and Family Plans Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Obstructive Sleep Apnea Treatment Services FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 3 General Background ............................................ 3 Coding/ Billing Information ................................... 6 References .......................................................... 6 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies
    [Show full text]
  • Amphetamine/Dextroamphetamine IR Generic
    GEORGIA MEDICAID FEE-FOR-SERVICE STIMULANT AND RELATED AGENTS PA SUMMARY Preferred Non-Preferred Amphetamine/dextroamphetamine IR generic Adzenys ER (amphetamine ER oral suspension) Armodafinil generic Adzenys XR (amphetamine ER dispersible tab) Atomoxetine generic Amphetamine/dextroamphetamine ER (generic Concerta (methylphenidate ER/SA) Adderall XR) Dextroamphetamine IR tablets generic Aptensio XR (methylphenidate ER) Focalin (dexmethylphenidate) Clonidine ER generic Focalin XR (dexmethylphenidate ER) Cotempla XR (methylphenidate ER disintegrating Guanfacine ER generic tablet) Methylin oral solution (methylphenidate) Daytrana (methylphenidate TD patch) Methylphenidate CD/CR/ER generic by Lannett Desoxyn (methamphetamine) [NDCs 00527-####-##] and Kremers Urban [NDCs Dexmethylphenidate IR generic 62175-####-##] (generic Metadate CD) Dexmethylphenidate ER generic Methylphenidate IR generic Dextroamphetamine ER capsules generic Modafinil generic Dextroamphetamine oral solution generic Quillichew ER (methylphenidate ER chew tabs) Dyanavel XR (amphetamine ER oral suspension) Quillivant XR (methylphenidate ER oral suspension) Evekeo (amphetamine tablets) Vyvanse (lisdexamfetamine) Methamphetamine generic Zenzedi 5 mg, 10 mg IR tablets (dextroamphetamine) Methylphenidate IR chewable tablets generic Methylphenidate ER/SA (generic Concerta) Methylphenidate ER/LA/SR (generic Ritalin LA, Ritalin SR, Metadate ER) Methylphenidate ER/SA 72 mg generic Methylphenidate oral solution generic Mydayis (amphetamine/dextroamphetamine ER) Ritalin LA 10 mg
    [Show full text]
  • MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide That Comes with Armodafinil Before You Start Taking It and Each Time You Get a Refill
    MEDICATION GUIDE Armodafinil Tablets, C-IV Read the Medication Guide that comes with armodafinil before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your condition or treatment. What is the most important information I should know about armodafinil? Armodafinil may cause serious side effects including a serious rash or a serious allergic reaction that may affect parts of your body such as your liver or blood cells. Any of these may need to be treated in a hospital and may be life-threatening. Stop taking armodafinil and call your doctor right away or get emergency help if you have any of these symptoms: • skin rash, hives, sores in your mouth, or your skin blisters and peels • swelling of your face, eyes, lips, tongue, or throat • trouble swallowing or breathing • fever, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine. If you have a severe rash with armodafinil, stopping the medicine may not keep the rash from becoming life- threatening or causing you to be permanently disabled or disfigured. Armodafinil is not approved for use in children for any medical condition. It is not known if armodafinil is safe or if it works in children under the age of 17. What is armodafinil? Armodafinil is a prescription medicine used to improve wakefulness in adults who are very sleepy due to one of the following diagnosed sleep disorders: • narcolepsy • obstructive sleep apnea (OSA).
    [Show full text]
  • Consensus Guideline for the Diagnosis and Treatment of Aromatic L-Amino
    Wassenberg et al. Orphanet Journal of Rare Diseases (2017) 12:12 DOI 10.1186/s13023-016-0522-z REVIEW Open Access Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency Tessa Wassenberg1, Marta Molero-Luis2, Kathrin Jeltsch3, Georg F. Hoffmann3, Birgit Assmann3, Nenad Blau4, Angeles Garcia-Cazorla5, Rafael Artuch2, Roser Pons6, Toni S. Pearson7, Vincenco Leuzzi8, Mario Mastrangelo8, Phillip L. Pearl9, Wang Tso Lee10, Manju A. Kurian11, Simon Heales12, Lisa Flint13, Marcel Verbeek1,14, Michèl Willemsen1 and Thomas Opladen3* Abstract Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms. In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease. Keywords: Aromatic l-amino acid decarboxylase deficiency, AADC deficiency, Neurotransmitter, Dopamine, Serotonin, Guideline, Infantile dystonia-parkinsonism, SIGN, GRADE German abstract Der Aromatische L-Aminosäuren Decarboxylase Mangel (AADCD) ist eine seltene autosomal rezessive neurometabolische Störung, die zu einem schweren kombinierten Mangel an Serotonin, Dopamin, Norepinephrin und Epinephrin führt.
    [Show full text]